| Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase A Ramirez, A Heimbach, J Gründemann, B Stiller, D Hampshire, LP Cid, ... Nature genetics 38 (10), 1184-1191, 2006 | 1434 | 2006 |
| Cancer linked to Alzheimer disease but not vascular dementia CM Roe, AL Fitzpatrick, C Xiong, W Sieh, L Kuller, JP Miller, MM Williams, ... Neurology 74 (2), 106-112, 2010 | 327 | 2010 |
| Alzheimer disease and cancer CM Roe, MI Behrens, C Xiong, JP Miller, JC Morris Neurology 64 (5), 895-898, 2005 | 241 | 2005 |
| HDDD2 is a familial frontotemporal lobar degeneration with ubiquitin‐positive, tau‐negative inclusions caused by a missense mutation in the signal peptide of progranulin O Mukherjee, P Pastor, NJ Cairns, S Chakraverty, JSK Kauwe, S Shears, ... Annals of Neurology: Official Journal of the American Neurological …, 2006 | 219 | 2006 |
| The structure of the presenilin 1 (S182) gene and identification of six novel mutations in early onset AD families. C RF, H M, F RA, F S, K E, T C, C R, L C, P G, H C, K K, M A, W M, B F, ... Nature Genetics 11 (2), 219-222, 1995 | 219 | 1995 |
| A common biological mechanism in cancer and Alzheimer's disease? MI Behrens, C Lendon, CM Roe Current Alzheimer Research 6 (3), 196-204, 2009 | 216 | 2009 |
| 3-Nitropropionic acid induces apoptosis in cultured striatal and cortical neurons MI Behrens, J Koh, LMT Canzoniero, SL Sensi, CA Csernansky, DW Choi Neuroreport 6 (3), 545-548, 1995 | 132 | 1995 |
| Clinical spectrum of Kufor‐Rakeb syndrome in the Chilean kindred with ATP13A2 mutations MI Behrens, N Brüggemann, P Chana, P Venegas, M Kägi, T Parrao, ... Movement Disorders 25 (12), 1929-1937, 2010 | 126 | 2010 |
| Susceptibility to apoptosis is enhanced in immature cortical neurons JW McDonald, MI Behrens, C Chung, T Bhattacharyya, DW Choi Brain research 759 (2), 228-232, 1997 | 124 | 1997 |
| Validation of the Spanish-language version of the Montreal Cognitive Assessment test in adults older than 60 years C Delgado, A Araneda, MI Behrens Neurología (English Edition) 34 (6), 376-385, 2019 | 118 | 2019 |
| E280A PS-1 mutation causes Alzheimer's disease but age of onset is not modified by ApoE alleles. L CL, M A, B IM, K KS, M L, N J, N R, M A, B F, W M, A M, A Viana JC, O J, ... Human Mutation 10 (3), 186-195, 1997 | 116 | 1997 |
| The serpin-enzyme complex receptor recognizes soluble, nontoxic amyloid-β peptide but not aggregated, cytotoxic amyloid-β peptide K Boland, M Behrens, D Choi, K Manias, DH Perlmutter Journal of Biological Chemistry 271 (30), 18032-18044, 1996 | 114 | 1996 |
| Ischemia enhances activation by Ca2+ and redox modification of ryanodine receptor channels from rat brain cortex R Bull, JP Finkelstein, J Gálvez, G Sánchez, P Donoso, MI Behrens, ... Journal of Neuroscience 28 (38), 9463-9472, 2008 | 111 | 2008 |
| Possible role of apamin‐sensitive K+ channels in myotonic dystrophy MI Behrens, P Jalil, A Serani, F Vergara, O Alvarez Muscle & Nerve: Official Journal of the American Association of …, 1994 | 103 | 1994 |
| Redox regulation of RyR-mediated Ca2+ release in muscle and neurons C Hidalgo, R Bull, MI Behrens, P Donoso Biological research 37 (4), 539-552, 2004 | 99 | 2004 |
| Recessively inherited parkinsonism: effect of ATP13A2 mutations on the clinical and neuroimaging phenotype N Brüggemann, J Hagenah, K Reetz, A Schmidt, M Kasten, I Buchmann, ... Archives of neurology 67 (11), 1357-1363, 2010 | 93 | 2010 |
| Nonmotor symptoms in genetic Parkinson disease M Kasten, L Kertelge, N Brüggemann, J Van Der Vegt, A Schmidt, V Tadic, ... Archives of neurology 67 (6), 670-676, 2010 | 90 | 2010 |
| Validación del instrumento Montreal Cognitive Assessment en español en adultos mayores de 60 años C Delgado, A Araneda, MI Behrens Neurología 34 (6), 376-385, 2019 | 88 | 2019 |
| ATP13A2 variants in early‐onset Parkinson's disease patients and controls A Djarmati, J Hagenah, K Reetz, S Winkler, MI Behrens, H Pawlack, ... Movement disorders: official journal of the Movement Disorder Society 24 (14 …, 2009 | 85 | 2009 |
| Nicotinamide, a poly [ADP-ribose] polymerase 1 (PARP-1) inhibitor, as an adjunctive therapy for the treatment of Alzheimer’s disease F Salech, DP Ponce, AC Paula-Lima, CD SanMartin, MI Behrens Frontiers in Aging Neuroscience 12, 255, 2020 | 73 | 2020 |
